Skip to content
DeepViews

Novavax Inc (NVAX) — 分析摘要

Novavax Inc(NVAX)的市值为2.10十亿美元,最近一年的营收同比增长了+64.7%。净利润率为39.2%。当前市盈率为-8.5倍。

核心要点

  • 营收同比变化+64.7%
  • 净利润率39.2%
  • 市盈率-8.5倍

与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比,NVAX的营收增长为+64.7%,市盈率为-8.5倍。

[XNAS]

Novavax Inc (NVAX)

$12.66

前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$2103.06M
企业价值
$1675.21M
市盈率
-8.5
股息率
10.07%
EV/EBITDA
-7.8
公司简介
关于
关于 Novavax Inc

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

行业

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

员工人数

749

总部

GAITHERSBURG, MD

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
41
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$-190.71M
总债务$291.49M
债务权益比N/A
现金及等价物$191.46M

现金流

经营现金流$-36.90M
自由现金流$-42.85M
自由现金流率-10.36%
P/FCF 比率-49.08
Source: Polygon.io · SEC EDGAR
股息
股息

年度每股股息

$1.27

股息收益率

10.07%

月度
最近除息日: 2007-12-13

股息历史

2007-12-13
CD$0.1062
2007-11-13
CD$0.1062
2007-10-11
CD$0.1062
2007-09-13
CD$0.1062
Source: Polygon.io
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。